Monday, December 10, 2012
Following a six-month review, Teva
Pharmaceuticals Industries Ltd.'s new management is drawing a clean line
with the company's past by refocusing R&D investment on key growth drivers
in complex and combination generics and branded CNS and respiratory drugs.
President and CEO Jeremy Levin
and CSO and President of Global R&D Michael Hayden detailed these growth
drivers for BioCentury in advance of unveiling the company's new strategy at an
investor meeting on Dec. 11.